Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Allarity Therapeutics, Inc. Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib October 22, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement October 10, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program October 03, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial September 16, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 13, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) September 11, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting July 26, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares July 24, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives July 22, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance June 27, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer June 25, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement May 20, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances May 14, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock May 07, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 May 06, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer May 02, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement April 29, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) April 17, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces 1-for-20 Reverse Stock Split April 04, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer March 27, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) March 25, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update March 08, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics to Present at Biomarkers 2024 February 28, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor December 12, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic December 05, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics to Present at Biomarkers Europe 2023 October 02, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib August 30, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics July 31, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives July 24, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering July 06, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Tickers ALLR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
